Last reviewed · How we verify
NCT05939960: GCTHCM
Application of a New Type of Whole Blood Coagulation Time Measurement in Evaluating the Hypercoagulable State of Malignant Tumors
trial testing CGT test in Neoplasm Metastasis in 354 participants. Status unknown.
28 February 2024
Quick facts
| Lead sponsor | Tianjin Medical University General Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 354 |
| Start date | 1 July 2023 |
| Primary completion | 28 February 2024 |
| Estimated completion | 30 September 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- CGT test
Conditions studied
- Neoplasm Metastasis — all drugs for Neoplasm Metastasis →
- Blood Coagulation Disorder With Shortened Coagulation Time (Disorder) — all drugs for Blood Coagulation Disorder With Shortened Coagulation Time (Disorder) →
- Venous Thromboembolism — all drugs for Venous Thromboembolism →
Sponsor
Tianjin Medical University General Hospital
Who can join
18 and older, any sex, with Neoplasm Metastasis or Blood Coagulation Disorder With Shortened Coagulation Time (Disorder). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Malignant tumors are closely related to deep vein thrombosis, Pulmonary embolism and other diseases. Tumor patients usually have a hypercoagulable state (HCS) in their blood, and the proportion of thrombosis caused by HCS is more than 10 times that of non tumor patients. Conventional clinical testing methods such as coagulation function, blood routine, and thromboelastography are difficult to directly evaluate the hypercoagulable state of tumor patients. In addition, the widely used Khorana score and Caprini score systems in clinical practice need to be improved in accurately reflecting the hypercoagulable state of tumor patients. Our team has established a complete new coagulation time measurement system, including general clotting time (GCT), platelet rich plasma clotting time (PRP-CT), and platelet poor plasma clotting time (PPP-CT), which may be a new and accurate method for evaluating tumor hypercoagulability. The GCT study aims to evaluate: 1. The time of GCT, PRP-CT, and PPP-CT for malignant tumors is shorter than that of normal individuals, and some patients are in a hypercoagulable state; 2. The shortened time of GCT, PRP-CT, and PPP-CT may be associated with future thrombosis; 3. Evaluating the relationship between shortened GCT system time and overall tumor survival Therefore, the GCT system evaluation may identify patients who are truly in a hypercoagulable state, providing monitoring indicators for subsequent anticoagulation; It can also be evaluated whether GCT time can reflect the prognosis of tumor patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05939960
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neoplasm Metastasis
Currently open trials in the same condition.
- NCT06912087 — Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC · Phase 1 · recruiting
- NCT06534580 — Virtual Reality for Advanced Cancer Pain · active not recruiting
- NCT06460961 — A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-68 · Phase 1 · active not recruiting
- NCT05573893 — PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Dat · recruiting
- NCT06046131 — Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression. · NA · recruiting
Other Tianjin Medical University General Hospital trials
Trials by the same sponsor.
- NCT06228781 — Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis · NA · not yet recruiting
- NCT07498595 — TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC · EARLY_PHASE1 · not yet recruiting
- NCT07498439 — TILs Therapy for Multiple Primary Early-Stage NSCLC · EARLY_PHASE1 · not yet recruiting
- NCT07018375 — The Effect of Oliceridine Patient-Controlled Intravenous Analgesia on Postoperative Chronic Pain After Video-Assisted Th · Phase 4 · not yet recruiting
- NCT07420296 — Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05939960 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University General Hospital
- Last refreshed: 11 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05939960.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing